The effect of Corynebacterium parvum on the humoral and cellular immune systems in patients with breast cancer.
Corynebacterium parvum, a Gram-positive anaerobic bacillus thought to be a strong immunological stimulant, has been shown to decrease tumour growth and prolong survival in patients with metastatic disease. Study of the effect of a single injection of a strain of C. parvum (CN. 6134) in six patients with stage IV metastatic breast cancer is reported. Results of laboratory tests to judge the physical and immunological effects of the drug infusion 24 hr post-treatment and weekly thereafter for 3 weeks are evaluated. Within 24 hr after C. parvum administration, most patients experienced fever and nausea. Blood counts and differential counts exhibited increased values 24 hr after treatment with a strong shift to the left. Lymphocyte and monocyte counts were greatly depressed at 24 hr. T-cell numbers in peripheral blood did not appear to be altered, but the picture with regard to B cells was less clear. Normal count was recovered by day 8. It appears that intravenous administration of C. parvum produces a temporary marked immunological depression which returns to essentially normal values in 8 days. The return to normal may be accompanied by resolution of the endotoxin-like syndrome of side-effects. Further study of patients receiving this therapeutic agent is important to detect enhancement of the anti-tumour immunological response precipitated.
D000368:Aged; D000917:Antibody Formation; D001402:B-Lymphocytes / Q000276:immunology; D001943:Breast Neoplasms / Q000276:immunology*; D003165:Complement System Proteins; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007958:Leukocyte Count; D008213:Lymphocyte Activation; D008875:Middle Aged; D011425:Propionibacterium acnes / Q000276:immunology*; D011947:Receptors, Antigen, B-Cell; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors
D011947:Receptors, Antigen, B-Cell; D003165:Complement System Proteins